Trade Summary

4 days ago, Karas Eric, serving as Chief Commercial Officer at ARS Pharmaceuticals, Inc. (SPRY), sold 25,000 shares at $10.00 per share, for a total transaction value of $250,000.00. Following this transaction, Karas Eric now holds 12,176 shares of SPRY.

This sale represents a 67.25% decrease in Karas Eric's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Friday, June 12, 2026 and publicly disclosed via SEC Form 4 filing on Saturday, June 13, 2026 (accepted Jun 12, 8:06 PM ET), 1 day after the trade was made.

ARS Pharmaceuticals, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.